Source: Bloomberg
Summary
L’Oréal is testing a new skin regeneration product called Re20, derived from donated cadaver cells. The product aims to help the skin regenerate itself. L’Oréal partnered with a biotech company to develop the product. Re20 is still in the testing phase and not yet available for public use. According to L’Oréal, the product has shown promising results in early trials.
Our Reading
The trend returns with a new name.
L’Oréal’s Re20 is reminiscent of previous skin regeneration products. The use of cadaver cells is not new in the beauty industry. L’Oréal’s partnership with a biotech company is a common practice in the field. The promise of “regenerating” skin is a familiar marketing claim. Re20 is just the latest iteration of the eternal quest for eternal youth.
Author: Evan Null
Re20: The Latest Chapter in the Story of Skin Regeneration
The Beauty Industry’s Fascination with Cadaver Cells
L’Oréal’s Foray into Biotech: A Growing Trend
The Promise of Regeneration: A Familiar Marketing Claim
The Quest for Eternal Youth: A Never-Ending Story
Re20 may be a new product, but the idea behind it is not new. The beauty industry has long been fascinated with the concept of skin regeneration, and the use of cadaver cells is just one of many approaches that have been explored. L’Oréal’s partnership with a biotech company is a common practice in the field, and the promise of “regenerating” skin is a marketing claim that has been made many times before. Despite this, Re20 has generated significant interest and attention, and its development is likely to be closely watched by industry observers.
